WO2001064671A3 - Derives d'haloimidazole et leur utilisation en tant qu'antagonistes des recepteurs muscariniques m3 et serotoniques 5-ht4 - Google Patents

Derives d'haloimidazole et leur utilisation en tant qu'antagonistes des recepteurs muscariniques m3 et serotoniques 5-ht4 Download PDF

Info

Publication number
WO2001064671A3
WO2001064671A3 PCT/FR2001/000590 FR0100590W WO0164671A3 WO 2001064671 A3 WO2001064671 A3 WO 2001064671A3 FR 0100590 W FR0100590 W FR 0100590W WO 0164671 A3 WO0164671 A3 WO 0164671A3
Authority
WO
WIPO (PCT)
Prior art keywords
represent
haloimidazole
serotoninergic
muscarinic
receptors
Prior art date
Application number
PCT/FR2001/000590
Other languages
English (en)
Other versions
WO2001064671A2 (fr
Inventor
Philippe R Bovy
Gilles Courtemanche
Olivier Crespin
Original Assignee
Sanofi Synthelabo
Philippe R Bovy
Gilles Courtemanche
Olivier Crespin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Philippe R Bovy, Gilles Courtemanche, Olivier Crespin filed Critical Sanofi Synthelabo
Priority to AU2001237517A priority Critical patent/AU2001237517A1/en
Publication of WO2001064671A2 publication Critical patent/WO2001064671A2/fr
Publication of WO2001064671A3 publication Critical patent/WO2001064671A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Composés de formule générale (I), dans laquelle R1 et/ou R2 représentent un atome d'halogène, et dans le cas où un des substituants R1 ou R2 ne représente pas un halogène celui-ci représente un atome d'hydrogène ou un groupe C1-4 alkyle, R représente un groupe C2-6 alkényle, un phényleun napthyle, un thienyle, pyrrolyle ou furyle, éventuellement substitué par un ou deux groupes R4, R3 et R4 représentent, indépendamment l'un de l'autre, un atome d'hydrogène, un atome d'halogène, un hydroxy, un groupe C1-4 alkyle, C1-4 alcoxy, cyano, nitro, C1-2 perfluoro alkyle, un hydroxyméthyle ou amino, n est égale à 1, 2 ou 3 ainsi que leurs sels, N-oxydes et hydrates. Application en thérapeutique.
PCT/FR2001/000590 2000-03-01 2001-02-28 Derives d'haloimidazole et leur utilisation en tant qu'antagonistes des recepteurs muscariniques m3 et serotoniques 5-ht4 WO2001064671A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001237517A AU2001237517A1 (en) 2000-03-01 2001-02-28 Haloimidazole derivatives, their preparation and therapeutic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/02597 2000-03-01
FR0002597A FR2805816B1 (fr) 2000-03-01 2000-03-01 Derives d'haloimidazole, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
WO2001064671A2 WO2001064671A2 (fr) 2001-09-07
WO2001064671A3 true WO2001064671A3 (fr) 2002-03-14

Family

ID=8847575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000590 WO2001064671A2 (fr) 2000-03-01 2001-02-28 Derives d'haloimidazole et leur utilisation en tant qu'antagonistes des recepteurs muscariniques m3 et serotoniques 5-ht4

Country Status (3)

Country Link
AU (1) AU2001237517A1 (fr)
FR (1) FR2805816B1 (fr)
WO (1) WO2001064671A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004546A1 (fr) * 1996-07-25 1998-02-05 Synthelabo Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
WO1999025710A1 (fr) * 1997-11-19 1999-05-27 Sanofi-Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
FR2772378A1 (fr) * 1997-12-12 1999-06-18 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004546A1 (fr) * 1996-07-25 1998-02-05 Synthelabo Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
WO1999025710A1 (fr) * 1997-11-19 1999-05-27 Sanofi-Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
FR2772378A1 (fr) * 1997-12-12 1999-06-18 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2805816B1 (fr) 2002-05-17
FR2805816A1 (fr) 2001-09-07
WO2001064671A2 (fr) 2001-09-07
AU2001237517A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
WO2001077107A8 (fr) Production et utilisation de composes heterocycliques
NO983970L (no) Tricykliske forbindelser, deres fremstilling og anvendelse
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
MY125359A (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods.
EP1527049B8 (fr) Composes heterocycliques fusionnes en tant qu'inhibiteurs de peptidase
MY114679A (en) Aroyl-piperidine derivatives
TW200606137A (en) Urea derivatives
DE60214591D1 (en) Pyrazolpyrimidinfungizide
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1235776T3 (da) Triphenylalkenderivater og deres anvendelse som selektive östrogenreceptormodulatorer
DK1045830T3 (da) Alfa-aminoamidderivater, der er anvendelige som analgetiske midler
DE69530094D1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
NO954072L (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
TR200100698T2 (tr) 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
WO2001062705A3 (fr) Derive d'aminoalcool
NZ513561A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
DK0618193T3 (da) Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
NO964698D0 (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
TNSN08161A1 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
ES2039221T3 (es) Procedimiento para producir derivados de piridazinona.
MX2007004482A (es) Derivados de piridina y la preparacion y el uso terapeutico de los mismos.
WO2002094770A3 (fr) Derives d'amino-alcool

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP